Roche Acquires TMEM16A Portfolio for CF Treatment
Roche has acquired Enterprise Therapeutics’s TMEM16A potentiator portfolio, which includes ETD002, a therapeutic candidate being evaluated in Phase 1 clinical trials for the treatment of cystic fibrosis (CF). The TMEM16A portfolio is focused on treatments for CF and other severe respiratory disorders characterized by excessive mucus…
